Age-related macular degeneration 8

Common Name(s)

Age-related macular degeneration 8

Age-related macular degeneration (ARMD) is a common complex disorder that affects the central region of the retina (macula) and is the leading cause of legal blindness in white Americans over age 65. Contributions of environmental factors and genetic susceptibility have been identified. The strongest nongenetic risk factor for ARMD is cigarette smoking. For a general phenotypic description and a discussion of genetic heterogeneity of ARMD, see {603075}.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 8" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 8" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Age-related macular degeneration 8" returned 4 free, full-text research articles on human participants. First 3 results:

The genetic variant rs4073 A→T of the Interleukin-8 promoter region is associated with the earlier onset of exudative age-related macular degeneration.
 

Author(s): Asta Hautamäki, Sanna Seitsonen, Juha M Holopainen, Jukka A Moilanen, Jarno Kivioja, Päivi Onkamo, Irma Järvelä, Ilkka Immonen

Journal: Acta Ophthalmol. 2015 Dec;93(8):726-33.

 

To study the association of the single nucleotide polymorphism (SNP) rs4073 in the interleukin-8 (IL-8) promoter region with the diagnosis and age of onset of exudative age-related macular degeneration (AMD) in association with the known genetic risk factors for AMD and tobacco smoking.

Last Updated: 15 Jan 2016

Go To URL
DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration.
 

Author(s): Younghee Kim, Valeria Tarallo, Nagaraj Kerur, Tetsuhiro Yasuma, Bradley D Gelfand, Ana Bastos-Carvalho, Yoshio Hirano, Reo Yasuma, Takeshi Mizutani, Benjamin J Fowler, Shengjian Li, Hiroki Kaneko, Sasha Bogdanovich, Balamurali K Ambati, David R Hinton, William W Hauswirth, Razqallah Hakem, Charles Wright, Jayakrishna Ambati

Journal: Proc. Natl. Acad. Sci. U.S.A.. 2014 Nov;111(45):16082-7.

 

Geographic atrophy, an advanced form of age-related macular degeneration (AMD) characterized by death of the retinal pigmented epithelium (RPE), causes untreatable blindness in millions worldwide. The RPE of human eyes with geographic atrophy accumulates toxic Alu RNA in response ...

Last Updated: 12 Nov 2014

Go To URL
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.
 

Author(s): Tanya Lushchyk, Sankha Amarakoon, José P Martinez-Ciriano, L Ingeborgh van den Born, G Seerp Baarsma, Tom Missotten

Journal: Acta Ophthalmol. 2013 Sep;91(6):e456-61.

 

Several clinical trials have established the efficacy of ranibizumab therapy administered every 4 weeks to treat exudative age-related macular degeneration (ARMD). Bevacizumab appears to be a cost-effective alternative to ranibizumab, although an optimal injection schedule has not ...

Last Updated: 20 Aug 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Age-related macular degeneration 8" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Cytokeratin 8 Level in Age-related Macular Degeneration
 

Status: Recruiting

Condition Summary: Age-related Macular Degeneration

 

Last Updated: 8 Mar 2016

Go to URL
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
 

Status: Recruiting

Condition Summary: Exudative Macular Degeneration; Retinal Hemorrhage

 

Last Updated: 22 Jan 2016

Go to URL